nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
Company profile
Ticker
NRIX
Exchange
Website
CEO
Arthur T. Sands
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Nurix, Inc.
SEC CIK
Corporate docs
Subsidiaries
DeCART Therapeutics Inc. ...
IRS number
270838048
NRIX stock data
Latest filings (excl ownership)
8-K
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
12 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
10-Q
2024 Q1
Quarterly report
10 Apr 24
8-K
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
10 Apr 24
8-K
Other Events
9 Apr 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
8-K
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
Latest ownership filings
4
Houte Hans van
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
4
Houte Hans van
15 Feb 24
4
Christine Ring
15 Feb 24
4
Gwenn Hansen
15 Feb 24
4
ARTHUR T SANDS
15 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
Financial summary
Quarter (USD) | Aug 23 | May 23 | Feb 23 | Nov 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 22 | Nov 21 | Nov 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm | 43.21 mm |
Cash burn (monthly) | 5.55 mm | 362.58 k | 13.34 mm | 13.20 mm | 13.71 mm | 12.17 mm |
Cash used (since last report) | 43.54 mm | 2.84 mm | 104.60 mm | 103.54 mm | 107.53 mm | 95.43 mm |
Cash remaining | -332.70 k | 40.36 mm | -61.40 mm | -60.33 mm | -64.33 mm | -52.22 mm |
Runway (months of cash) | -0.1 | 111.3 | -4.6 | -4.6 | -4.7 | -4.3 |
Institutional ownership, Q3 2023
94.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 13 |
Closed positions | 11 |
Increased positions | 41 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 350.70 bn |
Total shares | 46.27 mm |
Total puts | 11.20 k |
Total calls | 6.30 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.52 mm | $35.52 bn |
Baker Bros. Advisors | 3.88 mm | $30.51 bn |
Wasatch Advisors | 3.56 mm | $28.02 bn |
Deep Track Capital | 3.00 mm | $23.56 bn |
Redmile | 2.85 mm | $22.39 bn |
Vanguard | 2.71 mm | $21.34 bn |
ARK Investment Management | 2.59 mm | $20.38 bn |
T. Rowe Price | 2.38 mm | $18.69 bn |
Bain Capital Life Sciences Investors | 1.82 mm | $14.33 bn |
STT State Street | 1.77 mm | $13.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Houte Hans van | Common Stock | Sell | Dispose S | No | Yes | 10.0151 | 6,812 | 68.22 k | 68,333 |
13 Feb 24 | Houte Hans van | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Houte Hans van | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Christine Ring | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Christine Ring | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Gwenn Hansen | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 45,000 |
13 Feb 24 | Gwenn Hansen | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 150,000 | 1.31 mm | 150,000 |
13 Feb 24 | Arthur T Sands | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.72 | 800,000 | 6.98 mm | 800,000 |
News
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
12 Apr 24
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
12 Apr 24
Nurix Therapeutics Prices Upsized $175M Public Offering Of 10,166,667 Common Shares At $15/Share
12 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Press releases
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
16 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
11 Apr 24
Nurix Therapeutics Announces Proposed Public Offering
11 Apr 24
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
9 Apr 24
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
2 Apr 24